Neurogene
PublicNeurogene is now publicly traded
The data on this page reflects Neurogene's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
PIPE
Nov 4, 2024
Total Funding Raised
$478.5M
Company Overview
Neurogene is a biotechnology company focused on developing gene therapy solutions that leverage its EXACT gene regulation technology to transform complex neurological diseases into manageable conditions.
Sector
Biotech
AI Layer
Non-AI
Keywords
Neurogene Comparables
Compare Neurogene with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Encoded Therapeutics | 81% | |
| Mahzi Therapeutics | 71% | |
| Neela Therapeutics | 70% |
Neurogene Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| PIPE | Nov 4, 2024 | ||||
| Private Placement | Dec 19, 2023 | ||||
| Series B | Dec 16, 2020 | ||||
| Series A | Feb 12, 2019 |
Key People
Founding team and executive leadership
Neurogene Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Private Placement, PIPE, Series A, Series B |
| Redmile Group | Series B, Private Placement, PIPE, Series A |
| Janus Henderson Group | Series B, Private Placement |
| Avidity Partners | Series B, Private Placement |
| Commodore Capital | PIPE |
| ArrowMark Partners | Series B, Private Placement |
| Casdin Capital | Series B, Private Placement, PIPE |
Neurogene Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access